NASDAQ:EVLV

Evolv Technologies Holdings (NASDAQ:EVLV) Stock: Analyst "Buy" Rating Amid Strong Financial Performance and AI Security Growth

Font: Financial Modeling Prep  • May 13, 2026

Market Chart
  • Evolv Technologies Holdings (NASDAQ:EVLV) received a "Buy" rating from Craig-Hallum, signaling strong confidence in its 2026 financial outlook.
  • The AI security firm reported robust first-quarter revenue growth of 45% year-over-year, reaching $46.30 million, surpassing analyst expectations.
  • Evolv's subscription business is thriving, with annual recurring revenue (ARR) up 20% to $127.30 million, alongside improved profitability metrics like a reduced quarterly loss and increased Adjusted EBITDA.

Evolv Technologies Holdings is a leading security technology company. It specializes in developing and selling advanced AI-powered weapon screening systems. These innovative systems are engineered to efficiently detect potential threats without requiring individuals to stop or empty their pockets, enhancing both security and user experience. Evolv primarily serves critical sectors such as education, healthcare, sports, and entertainment venues, providing crucial public safety solutions.

On May 13, 2026, prominent analyst firm Craig-Hallum reaffirmed its "Buy" rating for Evolv, noting the stock price at $5.80. The firm expressed confidence that the company is "well positioned" to exceed its financial goals for the 2026 fiscal year. This optimistic analyst outlook is underpinned by Evolv's recent robust performance and sustained market demand for its security solutions.

This positive rating is strongly supported by Evolv's impressive financial results. As reported by MarketBeat, Evolv achieved a substantial 45% year-over-year increase in first-quarter revenue, reaching $46.30 million. This significant figure not only demonstrates strong revenue growth but also surpassed analyst expectations by over 5%. Following these encouraging results, the company proactively raised its revenue forecast for the full year of 2026, indicating continued confidence in its growth trajectory.

Evolv's robust subscription business also highlights significant growth. Its Annual Recurring Revenue (ARR), a key indicator of predictable income from subscriptions, surged by 20% to $127.30 million. Furthermore, as reported by Zacks, Evolv announced a smaller-than-expected quarterly loss of $0.03 per share, a notable improvement compared to an anticipated loss of $0.06 per share. This marks the third time in four quarters that Evolv has successfully beaten earnings estimates, showcasing consistent operational efficiency.

Beyond revenue and subscription growth, Evolv's profitability metrics are also showing strong improvement. Adjusted EBITDA, a crucial measure of a company's operating profit, reached $3.90 million for the quarter, a significant improvement from $2.10 million reported a year ago. CEO John Kedzierski emphasized that these results "reflect our progress in building a disciplined and predictable business," as highlighted by Business Wire, reinforcing confidence in Evolv's financial health and strategic direction.

Market Overview
ALP
AlphaTON Capital Corp. Common Stock
$0.38
43.34%
EZGO
EZGO Technologies Ltd.
$0.03
-14.64%
SOXS
Direxion Daily Semiconductor Bear 3X ETF
$8.22
-1.55%
SRXH
SRx Health Solutions Inc.
$0.17
12.10%
QUCY
Mainz Biomed N.V.
$1.69
26.12%
HAO
Haoxi Health Technology Limited
$0.03
-19.71%
ONDS
Ondas Holdings Inc.
$9.87
11.37%
POET
POET Technologies Inc.
$19.26
34.00%
NOK
Nokia Oyj
$14.62
-0.61%
EDBL
Edible Garden AG Incorporated
$0.46
23.63%